ArticleMolecules and cells2014
Homing and restorative effects of bone marrow-derived mesenchymal stem cells on cisplatin injured ovaries in rats.
Article in Molecules and cells, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 81 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
81 citing papers in PubMed, 3 syntheses or guidelines pooled it, 160 citations in OpenAlex.
- Cellular therapies in primary ovarian insufficiency and poor ovarian reserve: a systematic review.Journal of assisted reproduction and genetics · 2025Pooled it
- Bone marrow mesenchymal stem cells in premature ovarian failure: Mechanisms and prospects.Frontiers in immunology · 2022Pooled it
- Mesenchymal Stem Cells (MSCs) Therapy for Recovery of Fertility: a Systematic Review.Stem cell reviews and reports · 2018Pooled it
- Insulin-like growth factor 1 as a key paracrine mediator in mesenchymal stem cell-based intervention for ovarian ageing: a review.Journal of ovarian research · 2026Review
- hUCMSCs restore ovarian function via angiopoietin 1/2 rebalance in POI rats.Journal of ovarian research · 2025Article
- Harnessing extracellular vesicles from adipose-derived stem cells for the treatment of 4-vinylcyclohexene diepoxide-induced premature ovarian insufficiency.Stem cell research & therapy · 2025Article
- Precision medicine in premature ovarian insufficiency: a focus on the precision therapeutic strategies for mesenchymal stem cells.Stem cell research & therapy · 2025Review
- Observational
- Interceed combined with bone marrow mesenchymal stem cells improves endometrial receptivity of intrauterine adhesion.Regenerative therapy · 2024Review
- Application of Mesenchymal Stem Cells in Female Infertility Treatment: Protocols and Preliminary Results.Life (Basel, Switzerland) · 2024Review
- Bone marrow mesenchymal stem cells expressing Neat-1, Hotair-1, miR-21, miR-644, and miR-144 subsided cyclophosphamide-induced ovarian insufficiency by remodeling the IGF-1-kisspeptin system, ovarian apoptosis, and angiogenesis.Journal of ovarian research · 2024Article
- Evaluation of the therapeutic effect of very small stem cells from peripheral blood on the treatment of Premature Ovarian Failure: A pilot study.JBRA assisted reproduction · 2024Article
- Stem cell-based therapeutic potential in female ovarian aging and infertility.Journal of ovarian research · 2024Review
- Human Amniotic Epithelial Stem Cells Alleviate Autoimmune Premature Ovarian Insufficiency in Mice by Targeting Granulosa Cells via AKT/ERK Pathways.Stem cell reviews and reports · 2024Article
- Combination of bone marrow mesenchymal stem cells and moxibustion restores cyclophosphamide-induced premature ovarian insufficiency by improving mitochondrial function and regulating mitophagy.Stem cell research & therapy · 2024Article
- The mechanisms of MicroRNA 21 in premature ovarian insufficiency mice with mesenchymal stem cells transplantation : The involved molecular and immunological mechanisms.Journal of ovarian research · 2024Article
- Current Status and Future Prospects of Stem Cell Therapy for Infertile Patients with Premature Ovarian Insufficiency.Biomolecules · 2024Review
- Endometrial mesenchymal stromal/stem cells improve regeneration of injured endometrium in mice.Biological research · 2024Article
- Application of mesenchymal stem cell therapy for premature ovarian insufficiency: Recent advances from mechanisms to therapeutics.World journal of stem cells · 2024Article
- A new technology for the treatment of premature ovarian insufficiency: Cell sheet.Cell and tissue research · 2024Article
21 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature ovarian failure (POF) is a long-term adverse effect of chemotherapy treatment. However, current available treatment regimens are not optimal. Emerging evidence suggests that bone marrow-derived mesenchymal stem cells (BMSCs) could restore the structure and function of injured tissues, but the homing and restorative effects of BMSCs on chemotherapy injured ovaries are still not clear. In this study, we found that granulosa cell (GC) apoptosis induced by cisplatin was reduced when BMSCs were migrated to granulosa cells (GCs) in vitro. Chemotherapy-induced POF was induced by intraperitoneal injection of cisplatin in rats. BMSCs labeled with enhanced green fluorescent protein (EGFP) were injected into the rats via the tail vein to investigate the homing and distribution of BMSCs in vivo. The number of BMSCs in the ovarian hilum and medulla was greater than in the cortex, but no BMSCs were found in the follicles and corpus lutea. In addition, the BMSCs treatment group's antral follicle count and estradiol levels increased after 30 days, compared with the POF group. Hence, our study demonstrates that intravenously delivered BMSCs can home to the ovaries, and restore its structure and function in POF model rats.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.